Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children’s Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia Holliston, MA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...

Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors Holliston, MA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...

Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial Holliston, MA, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...

Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights Entered into securities purchase agreements with accredited investors for a $1.5 million private investment in public equity (PIPE) financing. The transaction closed on April 15, 2024.Received $0.5...

Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights Established a Research Collaboration with the McGowan Institute for Regenerative Medicine at the University of Pittsburgh to Study the Repair and Regeneration of the Colon following...